Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Transitional Cell 13Urinary Bladder Neoplasms 12Ureteral Neoplasms 4Neoplasm Metastasis 3Urologic Neoplasms 2Urogenital Neoplasms 2Carcinoma, Renal Cell 2Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Metastatic Urothelial Cancer 1Melanoma 1Male Urogenital Diseases 1Female Urogenital Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Advanced Bladder Cancer 1

Interventions

pembrolizumab 1lenvatinib 1enfortumab vedotin 1abemaciclib 1Tablets 1Standard of Care 1Radiosurgery 1Protons 1Nivolumab 1Epirubicin 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Adenoid Cystic × enfortumab vedotin × Clear all
NCT06891560 2026-03-20

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
34 enrolled

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡